Casdin Capital’s Ginkgo Bioworks DNA Stock Holding History

Casdin Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$362K	Hold	36,493	–	–	0.02%	42
2026 Q1	$224K	Hold	36,493	–	–	0.02%	40
2025 Q4	$303K	Hold	36,493	–	–	0.02%	37
2025 Q3	$532K	Hold	36,493	–	–	0.04%	32
2025 Q2	$411K	Hold	36,493	–	–	0.04%	31
2025 Q1	$208K	Hold	36,493	–	–	0.02%	42
2024 Q4	$358K	Hold	36,493	–	–	0.02%	38
2024 Q3	$297K	Sell	36,493 -1	-0%	-$10	0.02%	34
2024 Q2	$488K	Hold	36,494	–	–	0.04%	36
2024 Q1	$1.69M	Buy	+36,494	New	+$1.89M	0.13%	33
2022 Q2	–	Sell	-105,070	Closed	-$16.9M	–	44
2022 Q1	$16.9M	Sell	105,070 -3,152	-3%	-$614K	0.76%	28
2021 Q4	$36M	Sell	108,222 -71,848	-40%	-$34.1M	1.01%	29
2021 Q3	$83.5M	Buy	+180,070	New	+$87.7M	2.08%	18

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Casdin Capital's DNA Position: Q2 2026 in Review

Casdin Capital held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 36,493 shares worth $362K. The position accounts for 0.02% of the portfolio, ranked #42.

Casdin Capital first reported a position in DNA in Q3 2021 and has held it in 13 quarters since. The position peaked at $83.5M in Q3 2021. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Casdin Capital held 36,493 shares of Ginkgo Bioworks worth $362K as of Q2 2026.
Casdin Capital left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up 0.02% of Casdin Capital's portfolio in Q2 2026, its #42 holding.
Casdin Capital first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 13 quarters since.
Casdin Capital's Ginkgo Bioworks position peaked at $83.5M in Q3 2021.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.